Body Mass Index is simultaneously one of the most criticized numbers in medicine and one of the most used. It cannot tell muscle from fat, it was never designed for individual diagnosis, and it misses metabolic problems in some people while overstating them in others. Yet it remains the gateway criterion for GLP-1 treatment eligibility — including ours. Both halves of that sentence deserve an honest explanation.
What BMI actually is
BMI is your weight in kilograms divided by your height in meters squared — a formula devised in the 1830s by a Belgian statistician studying population averages, not individual health. The standard categories: under 18.5 is classified underweight, 18.5–24.9 normal, 25–29.9 overweight, and 30+ obese.
Its virtues are entirely practical: it costs nothing, requires only a scale and a tape measure, and correlates reasonably well with body fat across large populations. Decades of epidemiological research linking weight to diabetes, cardiovascular disease, and mortality were built on it, which is why clinical guidelines and drug trials inherited it as the standard entry criterion.
Its vices are equally real, and worth spelling out.
Where BMI gets it wrong
BMI cannot distinguish a pound of muscle from a pound of fat. A muscular athlete can register as "obese" while carrying 12% body fat; meanwhile a sedentary person with low muscle mass can have a "normal" BMI alongside metabolically dangerous visceral fat — a pattern sometimes called normal-weight obesity, affecting an estimated 10–25% of normal-BMI adults.
It also ignores fat distribution, which matters enormously: visceral fat around the organs drives metabolic disease far more than subcutaneous fat on hips and thighs. Two people with identical BMIs can carry opposite risk profiles. And the standard thresholds were derived primarily from European populations — at the same BMI, people of South and East Asian descent tend to carry more visceral fat and develop diabetes at lower BMIs (which is why several countries apply lower cutoffs), while the thresholds tend to overstate risk for some other groups.
None of this is controversial in medicine. BMI is a screening shortcut, not a verdict.
So why do eligibility rules still use it?
Because the clinical trials did. STEP 1 enrolled adults with BMI ≥ 30, or ≥ 27 with at least one weight-related condition; SURMOUNT-1 used the same structure. The FDA approvals mirror the trial populations, and prescribing guidelines mirror the approvals. When a provider applies the BMI 30 / BMI 27-plus-comorbidity rule, they are anchoring to the populations in which these medications were actually proven safe and effective.
There is also a defensible fairness argument: BMI is objective and uniformly measurable, which protects eligibility decisions from being arbitrary. The alternative measures that are more accurate — DEXA scans, waist-to-hip ratio protocols, metabolic panels — are better, and good providers use them as supplements, but they are not yet the standardized gatekeeping criteria.
The honest framing: BMI determines who the evidence covers, and the comorbidity clause (BMI ≥ 27 plus hypertension, prediabetes, sleep apnea, high cholesterol, and similar) is exactly where the system acknowledges that the number alone is insufficient.
What a good intake looks at beyond BMI
A BMI number starts the conversation; it should never end it. A responsible GLP-1 intake — including the one our partner physicians review — weighs the fuller picture.
Weight-related conditions: blood pressure, blood sugar history, cholesterol, sleep apnea, PCOS, fatty liver — these convert a borderline BMI into a clear clinical case, or flag that weight is not actually the primary problem to treat. Weight history: a decades-long pattern of cycling tells a different story than a recent gain with an identifiable cause. Medication history: drugs like certain antidepressants, steroids, and insulin drive weight gain, and that context matters. Contraindications: personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, pregnancy or plans for it.
And goals: a patient seeking to lose 15 pounds for aesthetics is a different clinical question than one seeking to escape prediabetes. Providers can and do decline to prescribe when the risk-benefit math does not support treatment — that judgment is the entire point of physician review.
Better numbers to know about your own body
If you want a more honest picture of your metabolic health than BMI alone provides, a few measures are worth knowing.
Waist circumference: measured at the navel, over 40 inches for men or 35 for women signals elevated visceral fat regardless of BMI — and it requires only a tape measure. Waist-to-height ratio: keeping waist under half your height is a remarkably robust screening rule across populations. Blood markers: fasting glucose, HbA1c, triglycerides, HDL, and ALT (a liver marker) together sketch your actual metabolic state — many patients learn more from one basic panel than from years of weighing themselves.
For body composition specifically, DEXA scans (often $50–150 at imaging centers) quantify fat mass, lean mass, and visceral fat directly. Smart scales using bioimpedance are far less accurate but can track direction over time. During GLP-1 treatment, these tools answer the question BMI never can: whether the weight you are losing is fat or muscle.
The bottom line
BMI is a population tool doing an individual's job, and medicine knows it. It persists in eligibility criteria because the trial evidence is organized around it and because objective gateways protect against arbitrary prescribing — not because anyone believes it captures your health in one number.
If your BMI is 30 or above, or 27 or above with a weight-related condition, you fall within the population where GLP-1 medications were studied, and an assessment with a licensed provider can determine whether treatment is appropriate for your specific situation. If your BMI is below the threshold but you carry metabolic risk, that is precisely the conversation to have with a clinician — and if your BMI is above it but your metabolic health is excellent, a good provider will weigh that too.
The number gets you to the conversation. The conversation is where medicine actually happens.
Quick answers: common questions
My BMI is 28 with no diagnosed conditions — can I qualify? Possibly: conditions like prediabetes, high blood pressure, sleep apnea, or PCOS often surface during a proper intake rather than before it. The assessment exists to find out; a provider may also determine treatment is not appropriate, and a good one will say so.
I am muscular and my BMI overstates my fat — what then? Tell the provider in your intake. Waist measurement, weight history, and labs all give them levers to assess your actual metabolic picture beyond the single number.
Is BMI different for different ethnicities? The standard thresholds fit some populations better than others — several countries use lower cutoffs for Asian populations because metabolic risk rises at lower BMIs. This is exactly the kind of context a clinician weighs.
What is a healthier number to track than BMI? Waist-to-height ratio (keep waist under half your height) and a basic metabolic panel tell you far more about your actual risk than BMI alone.